Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
|Articles|November 29, 2015
Stories of Survival: Brian Galgay and Karen Kent
This video features the compelling stories of EC survivors: Brian Galgay and Karen Kent.
Advertisement
This video was produced by The Esophageal Cancer Awareness Association. It features the compelling stories of EC survivors: Brian Galgay and Karen Kent.
Advertisement
Related to this article
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
4
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
5